Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProShares Releases 2 New Leveraged Biotech ETFs

Benzinga.com
1 Comment| June 23, 2015

{{labelSign}}  Favorites
{{errorMessage}}

ProShares has always been a fund company that isn’t afraid to introduce new products designed to maximize short-term moves in the market.

Two of their latest ETFs are aiming to capitalize on the red-hot biotech space. On Tuesday, the Proshares UltraPro NASDAQ Biotechnology (NASDAQ: UBIO) and ProShares UltraPro Short NASDAQ Biotechnology (NASDAQ: ZBIO) made their trading debut. These new funds are designed to provide triple-leveraged long and short exposure to a market cap weighted index of biotech companies.

Leveraging ETFs

Leveraged ETFs allow investors to commit smaller amounts of capital in order to produce an enhanced return. These funds are primarily used by aggressive traders and institutional fund managers who are willing to bet big on a specific industry or sector.

/www.benzinga.com/general/biotech/15/06/5618132/proshares-releases-2-new-leveraged-biotech-etfs alt=ProShares Releases 2 New Leveraged Biotech ETFs>Full story available on Benzinga.com

Click to enlargeMore...


{{labelSign}}  Favorites
{{errorMessage}}

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company